AbbVie Announces European Commission Approval of SKYRIZI® for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis Pharmaceutical Investing
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Pharmaceutical Investing
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis Life Science Investing
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026 Life Science Investing
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes Life Science Investing
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society Life Science Investing
